

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for Go Clear

☒ Limits Preview/Index History Clipboard Details

Limits: Review

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Cell Mol Life Sci. 1999 Oct 30;56(5-6):481-506.

[Related Articles](#), [Link](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives.

Roth W, Weller M.

Department of Neurology, University of Tübingen, School of Medicine, Germany.

Despite the considerable progress in modern tumor therapy, the prognosis for patients with glioblastoma, the most frequent malignant brain tumor, has not been substantially improved. Although cytoreductive surgery and radiotherapy are the mainstays of treatment for malignant glioma at present, novel cytotoxic drugs and immunotherapeutic approaches hold great promise as effective weapons against these malignancies. Thus, great efforts are being made to enhance antitumoral efficacy by combining various cytotoxic agents by novel routes of drug administration, or by combining anticancer drugs and immune modulators. Immunotherapeutic approaches include cytotoxic cytokines, targeted antibodies, and vaccination strategies. However, the success of most of these experimental therapies is prevented by the marked molecular resistance of glioma cells to diverse cytotoxic agents or by glioma associated immunosuppression. One promising experimental strategy to target glioma is the employment of death ligands such as CD95 (Fas/Apo1) ligand or Apo2 ligand (TRAIL). Specific proapoptotic approaches may overcome many of the obvious obstacles to a satisfactory management of malignant brain tumors.

Publication Types:


- Review
- Review, Academic

PMID: 11212300 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for treatment of glioblastoma AND blood brain barrier [Preview](#) [Go](#) [Clear](#)

☒ Limits Preview/Index **History** Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Limits: Review

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Search	Most Recent Queries	Time	Result
#19	Search treatment of glioblastoma AND blood brain barrier Limits: Review	15:06:20	16
#13	Search treatment of glioblastoma AND antibody Limits: Review	15:05:57	24
#9	Search treatment of glioblastoma Field: All Fields, Limits: Review	15:03:25	412
#7	Related Articles for PubMed (Select 7814155)	11:11:51	153
#6	Search x76534	11:10:46	1
#5	Search gpnmb and antibody	11:06:38	0
#2	Search riggins gj	10:56:18	39
#1	Search riggins and gpnmb	10:54:09	0

[Clear History](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Dec 6 2004 18:18:14